GLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Greenwich Lifesciences Inc (GLSI) does not present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has promising clinical trial results and a positive analyst rating, the lack of significant financial growth, neutral insider and hedge fund activity, and no recent trading signals suggest holding off on purchasing at this time.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 64.515, and moving averages are converging, signaling no clear trend. The stock is trading near resistance levels (R1: 27.724, R2: 29.327), which could limit further upward movement.
The FLAMINGO-01 trial has shown an 80% reduction in breast cancer recurrence rates in the non-HLA-A*02 arm, with global expansion plans for clinical sites. Analyst H.C. Wainwright raised the price target to $50, citing the potential to double the market for GLSI-100.
The stock has a 40% chance of declining in the short term (-1.88% next day, -5.61% next week, -2.02% next month). Additionally, financial performance remains weak, with no revenue and a net loss of -$4.15M in Q3 2025 despite YoY improvements.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of -$4.15M, though net income improved by 55.57% YoY. EPS increased to -0.3 (up 50% YoY), but gross margin remains at 0%.
H.C. Wainwright maintains a Buy rating and raised the price target from $39 to $50, citing positive efficacy data from the FLAMINGO-01 trial and the potential to double the market for GLSI-100.
